The clinical trial, sponsored by Tulane University School of Medicine, aimed to evaluate the combination of Elotuzumab, Selinexor, and Dexamethasone in patients with relapsed refractory multiple myeloma (RRMM). Despite the promising mechanism of action involving immune modulation and apoptosis induction, the study was withdrawn due to lack of funding from collaborator Karyopharm Therapeutics. The market for RRMM treatments is competitive, with several approved therapies, including Selinexor and Elotuzumab, already in use. The withdrawal of this trial may impact Tulane's positioning in the market and their ability to attract future collaborations or funding for similar studies.